Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 2, 2007, Pages 167.e1-167.e5

  Shamonki, Jaime M ^a   Salmon, Jane E ^a   Hyjek, Elizabeth ^a   Baergen, Rebecca N ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

antiphospholipid antibodies; antiphospholipid syndrome; complement; placenta; pregnancy

Indexed keywords

PARAFFIN; PHOSPHOLIPID ANTIBODY;

ARTICLE; BASEMENT MEMBRANE; CELL MEMBRANE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FETUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PLACENTA; PLACENTA INSUFFICIENCY; PREGNANCY; PRIORITY JOURNAL; TISSUE SECTION; TROPHOBLAST;

EID: 33846930928     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.10.879     Document Type: Article

References (27)

1. De Groot P.G., and Derksen R.H.W.M. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 3 (2005) 1854-1860
2. Derksen R.H., Khamashta M.A., and Branch D.W. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 50 (2004) 1028-1039
3. Salafia C.M., and Parke A.L. Pregnancy and rheumatic disease: placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Rheum Dis Clin North Am 23 (1997) 85-97
4. Magid M.S., Kaplan C., Sammaritano L.R., Peterson M., Druzin M.L., and Lockshin M.D. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 179 (1998) 226-234
5. Out H.J., Kooijman C.D., Bruinse H.W., and Derksen R.H. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 41 (1991) 179-186
6. Stone S., Pijnenborg R., Vercruysse L., et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 27 (2006) 457-467
7. Rand J.H., Wu X.X., Andree H.A., et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med 337 (1997) 154-160
8. Simantov R., LaSala J.M., Lo S.K., et al. Activation of cultured vascular endothelium by antiphospholipid antibodies. J Clin Invest 96 (1995) 2211-2219
9. Holers V.M., Girardi G., Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195 (2002) 212-220
10. Levine L.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 (2002) 752-763
11. Blank M., Cohen J., Toder V., and Shoenfeld Y. Induction of antiphospholipid syndrome in naïve mice with mouse lupus monoclonal and human polyclonal antibodies. Proc Natl Acad Sci U S A 88 (1991) 3069-3073
12. Branch D.W., Dudley D.J., Mitchell K.A., et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 163 (1990) 210-216
13. Piona A., La Rosa L., Tinacani A., Faden D., Magro G., and Grasso S. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naïve BALB/c mice. Scand J Immunol 41 (1995) 427-432
14. Girardi G., Berman J., Redecha P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112 (2003) 1644-1654
15. Thurman J.M., Kraus D.M., Girardi G., et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody induced pregnancy loss in mice. Mol Immunol 42 (2005) 87-97
16. Girardi G., Bulla R., Salmon J.E., and Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 43 (2006) 68-77
17. Baergen R.N. Manual of Benirschke and Kaufmann's pathology of the human placenta (2005), Springer, New York 81-90
18. Edens R.E., Linhardt R.J., Bell C.S., and Weiler J.M. Heparin and derivatized heparin inhibits zymosan and cobra venom factor activation of complement in serum. Immunopharmacology 27 (1994) 145-153
19. Myatt L. Placental adaptive responses and fetal programming. J Physiol 572; (2006) 25-30
20. Salmon J.E., Girardi G., and Volers V.M. Complement activation as a mediatory of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 61 (2002) 46-50
21. Harris C.L., and Morgan B.P. The many faces of the membrane regulators of complement. In: Szebeni J. (Ed). The complement system: novel roles in health and disease (2004), Kluwer Academic Publishers, Boston 129-166
22. Girardi G. Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation. J Reprod Immunol 66 (2005) 45-51
23. Ecker E., and Gross P. Anticomplementary power of heparin. J Infect Dis 44 (1929) 250-257
24. Kazatchkine M.D., Fearon D.T., Metcalfe D.D., Rosenberg R.D., and Austen K.F. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 67 (1981) 223-228
25. Ninomiya H., Kawashima Y., and Nagasawa T. Inhibition of complement-mediated hemolysis in paroxysmal nocturnal hemoglobinuria by heparin or low-molecular weight heparin. Br J Haematol 109 (2000) 875-881
26. Girardi G., Redecha P., and Salmon J.E. Heparin prevents antiphospholipid antibody-induce fetal loss by inhibiting complement activation. Nat Med 10; (2004) 1222-1226
27. Hillmen P., Hall C., March J.C.W., et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350 (2004) 552-559